Facebook
X
LinkedIn
ForwardOptimizing Treatment in Bronchiectasis: What’s New and What’s Next
Bronchiectasis (BE) and nontuberculous mycobacterial lung disease (NTM-LD) present ongoing challenges in clinical practice, with evolving treatment approaches offering new opportunities to improve patient care. This online educational activity will explore advances in the recognition and management of bronchiectasis, including identifying exacerbations and integrating new and emerging therapies into clinical practice.
The activity will also review the clinical presentation of NTM-LD and emerging treatment strategies to support informed treatment decisions and optimize patient management. Through expert-led education, learners will gain practical insights into evolving therapeutic approaches for these complex pulmonary conditions.
Target Audience
Pulmonologists and other healthcare professionals who are involved in the management of patients with bronchiectasis and NTM-LD.
Learning Objectives
Upon completion of this course, the learners should be able to:
- Recognize bronchiectasis exacerbations and apply updated treatment strategies, including the integration of new therapies, into clinical practice
- Identify NTM lung disease and incorporate emerging treatment strategies into patient management
Commercial Support Acknowledgment
This program was produced in collaboration with Insmed Incorporated.
Copyright Information
Copyright © 2026 American Thoracic Society. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without written permission from American Thoracic Society.
Course summary
Faculty
Ashley Losier, MD
Assistant Professor
Pulmonary, Critical Care & Sleep Medicine
Yale Medical School
New Haven, CT
Disclosures
Advisory Committee: Boehringer Ingelheim, Electromed, Inc., Inogen, Inc., Insmed, Inc., and MannKind Corporation
Gregory Tino, MD
Chief, Department of Medicine
Penn Presbyterian Medical Center
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Treasurer, American Thoracic Society
Philadelphia, PA
Disclosures
Grant/Contract: COPD Foundation
Planning Committee
Anne O’Donnell, MD
Professor, Medicine
Nehemiah and Naomi Cohen Chair
Pulmonary Disease Research Chief
Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Hospital
Washington, DC
Disclosures
Member, Bronchiectasis Guidelines Panel: American College of Chest Physicians
Executive committee member for US Bronchiectasis and NTM Care Center Network: COPD Foundation
Grant/Contract: Armata, AstraZeneca, Boehringer Ingelheim, COPD Foundation, GlaxoSmithKline, Insmed, Inc., Paratek Pharmaceuticals, Inc., and Renovian
Consultant: Boehringer Ingelheim, GlaxoSmithKline, and Zambon
Ashley Losier, MD
Assistant Professor
Pulmonary, Critical Care & Sleep Medicine
Yale Medical School
New Haven, CT
Disclosures
Advisory Committee: Boehringer Ingelheim, Electromed, Inc., Inogen, Inc., Insmed, Inc., and MannKind Corporation
Gregory Tino, MD
Chief, Department of Medicine
Penn Presbyterian Medical Center
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Treasurer, American Thoracic Society
Philadelphia, PA
Disclosures
Grant/Contract: COPD Foundation
Melissa Glasner, MSc
Manager Medical Content
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Amanda Noe
Senior Manager, Medical Education and Client Services
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Erika Fox
Senior Project Manager
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Content Reviewer
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships is present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found here: COI Policy for Official ATS Activities (thoracic.org)
All relevant financial relationships have been reviewed and mitigated.
Required Hardware/software
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers.
Additionally, this site and its activities are best viewed using the latest Operating System for your device.